302 related articles for article (PubMed ID: 36230683)
1. EZH2 Inhibition and Cisplatin as a Combination Anticancer Therapy: An Overview of Preclinical Studies.
Samaržija I; Tomljanović M; Novak Kujundžić R; Trošelj KG
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230683
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo.
Hu S; Yu L; Li Z; Shen Y; Wang J; Cai J; Xiao L; Wang Z
Cancer Biol Ther; 2010 Oct; 10(8):788-95. PubMed ID: 20686362
[TBL] [Abstract][Full Text] [Related]
3. EZH2 participates in malignant biological behavior of epithelial ovarian cancer through regulating the expression of BRCA1.
Li T; Cai J; Ding H; Xu L; Yang Q; Wang Z
Cancer Biol Ther; 2014 Mar; 15(3):271-8. PubMed ID: 24335192
[TBL] [Abstract][Full Text] [Related]
4. EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis.
Liu H; Li W; Yu X; Gao F; Duan Z; Ma X; Tan S; Yuan Y; Liu L; Wang J; Zhou X; Yang Y
Oncotarget; 2016 Aug; 7(35):56338-56354. PubMed ID: 27472460
[TBL] [Abstract][Full Text] [Related]
5. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic treatment combinations to effectively target cisplatin-resistant germ cell tumors: past, present, and future considerations.
Oing C; Skowron MA; Bokemeyer C; Nettersheim D
Andrology; 2019 Jul; 7(4):487-497. PubMed ID: 30924611
[TBL] [Abstract][Full Text] [Related]
7. miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer.
Sun J; Cai X; Yung MM; Zhou W; Li J; Zhang Y; Li Z; Liu SS; Cheung ANY; Ngan HYS; Li Y; Dai Z; Kai Y; Tzatsos A; Peng W; Chan DW; Zhu W
Oncogene; 2019 Jan; 38(4):564-580. PubMed ID: 30166592
[TBL] [Abstract][Full Text] [Related]
8. The expression and significance of the enhancer of zeste homolog 2 in lung adenocarcinoma.
Lv Y; Yuan C; Xiao X; Wang X; Ji X; Yu H; Wu Z; Zhang J
Oncol Rep; 2012 Jul; 28(1):147-54. PubMed ID: 22552406
[TBL] [Abstract][Full Text] [Related]
9. Interference with endogenous EZH2 reverses the chemotherapy drug resistance in cervical cancer cells partly by up-regulating Dicer expression.
Cai L; Wang Z; Liu D
Tumour Biol; 2016 May; 37(5):6359-69. PubMed ID: 26631032
[TBL] [Abstract][Full Text] [Related]
10. Enhancer of zeste homolog 2 promotes cisplatin resistance by reducing cellular platinum accumulation.
Sun S; Zhao S; Yang Q; Wang W; Cai E; Wen Y; Yu L; Wang Z; Cai J
Cancer Sci; 2018 Jun; 109(6):1853-1864. PubMed ID: 29630768
[TBL] [Abstract][Full Text] [Related]
11. Reciprocal epigenetic remodeling controls testicular cancer hypersensitivity to hypomethylating agents and chemotherapy.
Singh R; Fazal Z; Bikorimana E; Boyd RI; Yerby C; Tomlin M; Baldwin H; Shokry D; Corbet AK; Shahid K; Hattab A; Freemantle SJ; Spinella MJ
Mol Oncol; 2022 Feb; 16(3):683-698. PubMed ID: 34482638
[TBL] [Abstract][Full Text] [Related]
12. Electron transfer-based combination therapy of cisplatin with tetramethyl-p-phenylenediamine for ovarian, cervical, and lung cancers.
Luo T; Yu J; Nguyen J; Wang CR; Bristow RG; Jaffray DA; Zhou XZ; Lu KP; Lu QB
Proc Natl Acad Sci U S A; 2012 Jun; 109(26):10175-80. PubMed ID: 22685209
[TBL] [Abstract][Full Text] [Related]
13. FBP1 knockdown decreases ovarian cancer formation and cisplatin resistance through EZH2-mediated H3K27me3.
Xiong X; Lai X; Zhang J; Meng Q; Wang P; Qin S; Liu W; Wang Y; Yao Z; Wang D; Li X; Liu Z; Miao H
Biosci Rep; 2022 Sep; 42(9):. PubMed ID: 36000567
[TBL] [Abstract][Full Text] [Related]
14. Attenuated Salmonella-delivered PD-1 siRNA enhances the antitumor effects of EZH2 inhibitors in colorectal cancer.
Lv M; Guo S; Zhang X; Zou Y; Chen Q; Zang C; Huang S; Hu Y; Wang Y; Wang Q; Zhong J
Int Immunopharmacol; 2023 Nov; 124(Pt A):110918. PubMed ID: 37708707
[TBL] [Abstract][Full Text] [Related]
15. Interfering EZH2 Expression Reverses the Cisplatin Resistance in Human Ovarian Cancer by Inhibiting Autophagy.
Sun Y; Jin L; Liu JH; Sui YX; Han LL; Shen XL
Cancer Biother Radiopharm; 2016 Sep; 31(7):246-52. PubMed ID: 27610467
[TBL] [Abstract][Full Text] [Related]
16. LncRNA UCA1 promotes cisplatin resistance in gastric cancer via recruiting EZH2 and activating PI3K/AKT pathway.
Dai Q; Zhang T; Pan J; Li C
J Cancer; 2020; 11(13):3882-3892. PubMed ID: 32328192
[No Abstract] [Full Text] [Related]
17. Overcoming Chemotherapy Resistance in Germ Cell Tumors.
Országhová Z; Kalavska K; Mego M; Chovanec M
Biomedicines; 2022 Apr; 10(5):. PubMed ID: 35625709
[TBL] [Abstract][Full Text] [Related]
18. A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
[TBL] [Abstract][Full Text] [Related]
19. HOXB13 networking with ABCG1/EZH2/Slug mediates metastasis and confers resistance to cisplatin in lung adenocarcinoma patients.
Zhan J; Wang P; Li S; Song J; He H; Wang Y; Liu Z; Wang F; Bai H; Fang W; Du Q; Ye M; Chang Z; Wang J; Zhang H
Theranostics; 2019; 9(7):2084-2099. PubMed ID: 31037158
[No Abstract] [Full Text] [Related]
20. Interactions of cisplatin with non-DNA targets and their influence on anticancer activity and drug toxicity: the complex world of the platinum complex.
Mezencev R
Curr Cancer Drug Targets; 2015; 14(9):794-816. PubMed ID: 25431081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
